Reeling from a regulatory setback last month, Sage Therapeutics is to undergo a major restructuring in the runup to its launch of postpartum depression drug Zur 1 September 2023
Less than six months after raising $100 million in a Series A financing, neuromedicines company Rapport Therapeutics has added another $150 million to its coffe 24 August 2023
Neuroscience-focused Neurocrine Biosciences has won US Food and Drug Administration (FDA) approval for Ingrezza (valbenazine) capsules to treat adults with chor 21 August 2023
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.